|
| 36603175 | Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. | J Clin Oncol | 2023 |
| 37497337 | Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit. | Cancer Res Commun | 2023 |
| 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 |
| 37027520 | Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer. | Oncologist | 2023 |
| 36750617 | Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. | Commun Med (Lond) | 2023 |
| 34729846 | Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. | Head Neck | 2022 |
| 35551160 | Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma. | Melanoma Res | 2022 |
| 36312666 | Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma. | Cureus | 2022 |
| 36328377 | FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. | J Immunother Cancer | 2022 |
| 35952316 | Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. | JCO Precis Oncol | 2022 |
| 34928709 | Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). | J Clin Oncol | 2022 |
| 34476329 | Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. | JCO Precis Oncol | 2021 |
| 33509808 | Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. | Clin Cancer Res | 2021 |
| 34380663 | Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). | J Immunother Cancer | 2021 |
| 34485815 | Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. | JNCI Cancer Spectr | 2021 |
| 32455336 | Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. | JNCI Cancer Spectr | 2020 |
| 31811950 | Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. | Clin Gastroenterol Hepatol | 2020 |
| 31753113 | Current Clinical Trials in the Treatment of Advanced Melanomas. | Surg Clin North Am | 2020 |
| 33269159 | Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib. | Cureus | 2020 |
| 33354554 | Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer. | South Asian J Cancer | 2020 |
| 32699281 | Label-free detection of rare circulating tumor cells by image analysis and machine learning. | Sci Rep | 2020 |
| 31487684 | Engaging Community-Based Cancer Physicians: Experience of the Memorial Sloan Kettering Cancer Center Cancer Alliance. | J Natl Compr Canc Netw | 2019 |
| 30104290 | Dramatic Response to Concurrent Anti-PD-1 Therapy and Radiation in Resistant Tumors with Sarcomatoid Differentiation. | Oncologist | 2019 |
| 29157870 | Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. | J Diabetes Complications | 2018 |
| 28636851 | First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 |
| 27060850 | Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. | Int J Cancer | 2016 |
| 26658227 | Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). | Pharmacogenet Genomics | 2016 |
| 27881709 | Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). | Oncologist | 2016 |
| 27269740 | Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. | Lancet Oncol | 2016 |
| 26981948 | Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. | N Engl J Med | 2016 |
| 25815245 | Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience. | Springerplus | 2015 |
| 26272427 | Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). | Clin Genitourin Cancer | 2015 |
| 25932372 | A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma. | Springerplus | 2015 |
| 25704439 | Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. | Lancet Oncol | 2015 |
| 24687927 | KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). | Clin Cancer Res | 2014 |
| 24925349 | Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. | J Natl Cancer Inst | 2014 |
| 24512953 | Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. | Clin Colorectal Cancer | 2014 |
| 23814525 | Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment. | J Oncol Pract | 2013 |
| 24104062 | Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. | Cancer Discov | 2013 |
| 21422991 | Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. | Am J Clin Oncol | 2012 |
| 22474202 | Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. | JAMA | 2012 |
| 21607582 | Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities. | Breast Cancer Res Treat | 2011 |
| 21218460 | A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. | Cancer | 2010 |
| 18193036 | The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. | Nat Cell Biol | 2008 |
| 18270974 | Can surgeons improve survival in stage IV melanoma? | J Surg Oncol | 2008 |
| 18022553 | Current immunotherapeutic strategies in malignant melanoma. | Surg Oncol Clin N Am | 2007 |
| 16777690 | A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. | Cancer Invest | 2006 |
| 16361618 | Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. | J Clin Oncol | 2005 |
| 16135464 | Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. | J Clin Oncol | 2005 |
| 16230673 | Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. | J Clin Oncol | 2005 |